Istaroxime
Istaroxime is in phase II clinical trials for the treatment of heart failure by CVie Therapeutics (A division of Lee's Pharmaceutical).
The compound was originally discovered by Sigma-Tau, then CVie Therapeutics acquired the rights of the drug.
General Information
Update Date：2015-10-14
- Drug Name：
- Istaroxime
- Research Code：
- Debio-0614; PST-2744; ST-2744
- Trade Name：
- MOA：
- Na+/K+-ATPase inhibitor
- Indication：
- Heart failure
- Status：
- Phase II (Active)
- Company：
- Sigma-Tau (Originator) , Lee's pharmaceuticals
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-10-14
|
Molecular Weight | 360.49 | ||||||||||||
| Formula | C21H32N2O3 | |||||||||||||
| CAS No. | 203737-93-3 (Istaroxime); | |||||||||||||
| Chemical Name | Androstane-3,6,17-trione, 3-[O-(2-aminoethyl)oxime], (5a)- | |||||||||||||
| Istaroxime （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||